A Meta-analysis of Arsenic Exposure and Lung Function: Is There Evidence of Restrictive or Obstructive Lung Disease?
- 146 Downloads
Purpose of Review
Hundreds of millions of people worldwide are exposed to arsenic via contaminated water. The goal of this study was to identify whether arsenic-associated lung function deficits resemble obstructive- or restrictive-like lung disease, in order to help illuminate a mechanistic pathway and identify at-risk populations.
We recently published a qualitative systematic review outlining the body of research on arsenic and non-malignant respiratory outcomes. Evidence from several populations, at different life stages, and at different levels of exposure showed consistent associations of arsenic exposure with chronic lung disease mortality, respiratory symptoms, and lower lung function levels. The published review, however, only conducted a broad qualitative description of the published studies without considering specific spirometry patterns, without conducting a meta-analysis, and without evaluating the dose-response relationship.
We searched PubMed and Embase for studies on environmental arsenic exposure and lung function. We performed a meta-analysis using inverse-variance-weighted random effects models to summarize adjusted effect estimates for arsenic and forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio. Across nine studies, median water arsenic levels ranged from 23 to 860 μg/L. The pooled estimated mean difference (MD) comparing the highest category of arsenic exposure (ranging from > 11 to > 800 μg/L) versus the lowest (ranging from < 10 to < 100 μg/L) for each study for FEV1 was – 42 mL (95% confidence interval (CI) − 70, − 16) and for FVC was – 50 mL (95% CI − 63, − 37). Three studies reported effect estimates for FEV1/FVC, for which there was no evidence of an association; the pooled estimated MD was 0.01 (95% CI − 0.005, 0.024). This review supports that arsenic is associated with restrictive impairments based on inverse associations between arsenic and FEV1 and FVC, but not with FEV1/FVC. Future studies should confirm whether low-level arsenic exposure is a restrictive lung disease risk factor in order to identify at-risk populations in the USA.
KeywordsArsenic Epidemiology Meta-analysis Restrictive lung disease Spirometry Systematic review
American Thoracic Society
Cystic fibrosis transmembrane conductance
European Respiratory Society
Ratio of FEV1 to FVC
Forced expiratory volume in one second
Forced vital capacity
Pulmonary function test
This work was supported by the National Institute of Environmental Health Sciences at the National Institutes of Health (grant numbers R01ES021367, 1R01ES025216, 5P30ES009089, and P42ES010349).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.World Health Organization. Exposure to arsenic: a major public health concern. http://www.who.int/ipcs/features/arsenic.pdf. Published 2010. Accessed November 15, 2016.
- 2.National Research Council. Critical aspects of EPA’s IRIS assessment of inorganic arsenic: interim report. Washington, DC: The National Academies Press; 2014.Google Scholar
- 11.Parvez F, Chen Y, Yunus M, Olopade C, Segers S, Slavkovich V, et al. Arsenic exposure and impaired lung function. Findings from a large population-based prospective cohort study. Am J Respir Crit Care Med. 2013;188(7):813–9. https://doi.org/10.1164/rccm.201212-2282OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology a proposal for reporting. JAMA. 2000;283(15):2008–12. https://doi.org/10.1001/jama.283.15.2008.
- 23.Steinmaus C, Ferreccio C, Acevedo J, Balmes JR, Liaw J, Troncoso P, et al. High risks of lung disease associated with early-life and moderate lifetime arsenic exposure in northern Chile. Toxicol Appl Pharmacol. 2016;313:10–5. https://doi.org/10.1016/j.taap.2016.10.006.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Egger M, Davey-Smith G, Altman D (eds). Systematic reviews in health care: meta-analysis in context, 2nd edition. London: BMJ Publishing Group; 2001. https://doi.org/10.1002/9780470693926.
- 25.Smith AH, Yunus M, Khan AF, Ercumen A, Yuan Y, Smith MH, et al. Chronic respiratory symptoms in children following in utero and early life exposure to arsenic in drinking water in Bangladesh. Int J Epidemiol. 2013;42(4):1077–86. https://doi.org/10.1093/ije/dyt120.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997;315(7109):629–34. https://doi.org/10.1136/bmj.315.7109.629.
- 30.Harbord RM, Higgins JPT. Meta-regression in Stata. Stata J. 2008;8(4):493–519.Google Scholar
- 38.Choudhury S, Gupta P, Ghosh S, Mukherjee S, Chakraborty P, Chatterji U, et al. Arsenic-induced dose-dependent modulation of the NF-κB/IL-6 axis in thymocytes triggers differential immune responses. Toxicology. 2016;357-358:85–96. https://doi.org/10.1016/j.tox.2016.06.005.CrossRefPubMedGoogle Scholar
- 40.•• Mazumdar M, Christiani DC, Biswas SK, Ibne-Hasan OS, Kapur K, Hug C. Elevated sweat chloride levels due to arsenic toxicity. N Engl J Med. 2015;372(6):582–3. https://doi.org/10.1056/NEJMc1413312. This study shows evidence that arsenic is associated with elevated sweat chloride levels among persons exposed to arsenic in the absence of a genetic diagnosis of cystic fibrosis. CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Bomberger JM, Coutermarsh BA, Barnaby RL, Stanton BA. Arsenic promotes ubiquitinylation and lysosomal degradation of cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels in human airway epithelial cells. J Biol Chem. 2012;287(21):17130–9. https://doi.org/10.1074/jbc.M111.338855.CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Broeckaert F, Clippe A, Knoops B, Hermans C, Bernard A. Clara cell secretory protein (CC16): features as a peripheral lung biomarker. Ann N Y Acad Sci. 2000;923:68–77. https://doi.org/10.1111/j.1749-6632.2000.tb05520.x.CrossRefPubMedGoogle Scholar
- 48.Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJR, et al. Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study. Am J Respir Crit Care Med. 2009;180(5):407–14. https://doi.org/10.1164/rccm.200812-1966OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 51.IHME. Epi visualization. http://ghdx.healthdata.org/gbd-results-tool?params=querytool-permalink/fc7c45515025010a96c2a7dd49ed751f. Published 2016. Accessed October 27, 2016.
- 55.• Sherwood CL, Lantz RC. Lung cancer and other pulmonary disease. In: States JC, ed. Arsenic: exposure sources, health risks, and mechanisms of toxicity. John Wiley & Sons, Inc.; 2015:137–162. https://doi.org/10.1002/9781118876992.ch7. This chapter reviews possible mechanisms for arsenic-associated lung disease, both malignant and non-malignant.